A Phase IIA Study to Determine the Safety and Efficacy of A NCI-Supplied Agent: G3139 (NSC 683428, IND 58842) and Imatinib Mesylate in Patients With Refractory or Relapsed Gastrointestinal Stromal Tumor

Trial Profile

A Phase IIA Study to Determine the Safety and Efficacy of A NCI-Supplied Agent: G3139 (NSC 683428, IND 58842) and Imatinib Mesylate in Patients With Refractory or Relapsed Gastrointestinal Stromal Tumor

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Imatinib (Primary) ; Oblimersen (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 28 May 2010 Actual patient number (1) added as reported by ClinicalTrials.gov.
    • 28 May 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Actual end date (January 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top